Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1347858/000155837022016728/xxii-20220930x10q.htm
January 2023
November 2022
November 2022
November 2022
September 2022
September 2022
August 2022
July 2022
June 2022
June 2022
Exhibit 99.1
22nd Century Group (Nasdaq: XXII) Reports Business Highlights and Financial Results for the Third Quarter 2022
● | Accelerating VLN® Sales in Colorado and Illinois, Launching in Four Corners States to Capture Market Share and Volume |
● | GVB Biopharma Acquisition Growing Revenue on Increased Volumes |
● | Third Quarter Net Sales $19.4 Million, Up 148% from the Third Quarter 2021 |
● | Strong Balance Sheet to Support Strategic Initiatives Including Accelerated VLN® Expansion |
BUFFALO, N.Y., November 8, 2022 (Globe Newswire) — 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today reported results for the third quarter ended September 30, 2022, and provided an update on recent business highlights. The Company will host a live audio webcast today at 10:00 a.m. E.T.
James A. Mish, Chief Executive Officer of 22nd Century Group, stated: “The past few months have demonstrated tremendous commercial progress in 22nd Century’s reduced nicotine tobacco and hemp/cannabis businesses. Our VLN® product launch has expanded from the exceptional pilot in Chicago to now five states. We plan to expand that base to as many as 18 states over the next twelve months. Doing so would give us access to more than half the $80 billion U.S. tobacco market and position us in most, if not all, of the states that have enacted MRTP excise tax provisions favorable to our unique product authorization. Even just a 1% share, which we view as eminently achievable based on our pilot results, would be transformative to our revenue line. The FDA is also continuing to advance its interests in transformative menthol and reduced nicotine policies, and 22nd Century is positioned at the forefront of this opportunity with the only MRTP authorized 95% reduced nicotine combustible cigarette and years of clinical research documenting the benefits of our products.
“We also reported our first full quarter of hemp/cannabis revenue benefitting from the acquisition of GVB Biopharma this spring. We are now the largest merchant market supplier of CBD in North America and positioned to grow that stake even further. We are moving quickly to complete the startup of our new Prineville crude extraction plant and secure additional certifications for our facilities that will further differentiate our products and make us the premier supplier of hemp-derived extracts and ingredients to consumer and wellness products. Success in these endeavors will enable us to increase our gross margin on this portion of our business and compete from a position of strength in a much larger active ingredient market once FDA announces its highly anticipated new product standards for the industry.
“With a strengthened balance sheet and a clear path to increased revenue and gross margins, we are excited about the path forward as we work to rapidly drive market share and create operating scale across our business units,” concluded Mish.
Recent Key Financial and Business Highlights
Tobacco Business
● | 22nd Century Group has moved aggressively into its commercial launch program for VLN®, leveraging its exceptional pilot results to develop an efficient, reproducible VLN® Sales Launch Blueprint that focuses resources to achieve the greatest returns. |
o | The launch blueprint is designed to be repeatable as the Company expands VLN® availability to new markets. |
o | The Company expects to gain significant market share in a new market based on consumer adoption. |
o | Consumers have described VLN® as “game-changing” and “lifesaving”. |
● | 22nd Century has refined its VLN® rollout strategy to focus on going deeper into select geographies and markets with high cigarette volume and large adult smoker populations. |
o | The Company estimates that every 1% share of the U.S. retail market equates to approximately $800 million in retail sales, which is $500 million in revenue for a premium cigarette manufacturer. |
o | 22nd Century will also prioritize states with Modified Risk Tobacco Product (MRTP) state excise tax savings, which can be used toward adult consumer incentives, expand distribution, and additional programming to raise awareness, education, and trial among adult smokers of its unique products. |
● | 22nd Century announced that it is expanding its retail sales presence in Illinois following exceptional results in its Chicago pilot. |
● | The Company subsequently launched VLN® in Colorado through its expanded network of retailers and distribution partners, including Circle K, Eagle Rock Distributing Company, and Creager Mercantile. |
o | The Colorado VLN® distribution plan includes thousands of retail sites and numerous new retailers supported by 22nd Century’s distribution partnerships. |
o | The Company is initially acting on approximately 3,000 locations across the state where VLN® will be available. |
● | The Company also announced that it will launch VLN® in three additional states – Arizona, New Mexico, and Utah – covering the Four Corners region. |
o | Expanding into the Four Corners gives VLN® access to concentrated centers of adult smokers allowing the Company to market VLN® in a streamlined and efficient manner where resources can be pooled and focused. |
o | New Mexico and Utah have an MRTP tax benefit that 22nd Century Group can leverage similar to its activities in Colorado. |
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1347858/000155837022016728/xxii-20220930x10q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by 22Nd Century Group, Inc..
22Nd Century Group, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:
Rating
Learn More![]()
The increase in gross profit and gross profit as a percent of sales for the nine months ended September 30, 2022, compared to the nine months ended September 30, 2021, was primarily driven by favorable tobacco volume, price, and mix, and new hemp/cannabis profit that was not reflected in the prior year period.
The increase in gross profit and gross profit as a percent of sales for the three months ended September 30, 2022, compared to the three months ended September 30, 2021, was driven by higher volumes in both tobacco and hemp/cannabis, partially offset by an inventory write-down of $281.
o Net revenues from tobacco related products was $11,535, an increase of 47.7% from 2021 primarily driven by volume increases in the number of cartons sold, price increases, and favorable mix for filtered cigar and cigarettes (including export cigarettes).
Under the new leadership at the FDA and Center for Tobacco Products ("CTP"), we believe that the FDA will refocus on implementing its ground-breaking Comprehensive Plan for Tobacco and Nicotine Regulation, in particular the Agency's plan to cap the amount of nicotine in combustible cigarettes to a "minimally or non-addictive" level.
The increase in SG&A expense during the nine months ended September 30, 2022, as compared to the nine months ended September 30, 2021, was driven by $4,149 of GVB expenses that were not reflected in the prior year period, and increases in severance charges and accelerated equity compensation expense of $1,928, strategic consulting expenses of $3,575, additional personnel expenses of $867 and sales and marketing expense of $906 due to the acceleration of our VLN launch, one-time transaction costs related to the acquisition of GVB of $882, legal fees of $529, and other expenses of $673.
As described below, on July...Read more
Our cash, cash equivalents and...Read more
o Research and development expenses...Read more
Hemp/cannabis gross profit was negligible...Read more
Management believes the estimates, assumptions...Read more
Net cash (used in) operating...Read more
Important factors that could cause...Read more
To reflect this difference in...Read more
The increase in net revenue...Read more
Unrealized gain (loss) on investment...Read more
22nd Century's cash requirements in...Read more
? The Company announced that...Read more
? Net revenues for the...Read more
The increase in net revenue...Read more
The increase was due to...Read more
? Gross profit for the...Read more
We believe that recent political...Read more
22nd Century is already seeing...Read more
These transactions effect the (i)...Read more
The acquisition of GVB has...Read more
This decrease in working capital...Read more
The Company is selectively deploying...Read more
Since 2011, we have provided...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
22Nd Century Group, Inc. provided additional information to their SEC Filing as exhibits
Ticker: XXII
CIK: 1347858
Form Type: 10-Q Quarterly Report
Accession Number: 0001558370-22-016728
Submitted to the SEC: Tue Nov 08 2022 7:00:49 AM EST
Accepted by the SEC: Tue Nov 08 2022
Period: Friday, September 30, 2022
Industry: Cigarettes